Cipla faces revenue and margin pressure ahead of Revlimid patent expiry
Live Events
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
ET Intelligence Group: Cipla has underperformed the sector indices in the past twelve months following expected pressure on revenue and margin amid Revlimid patent expiry next year. The company expects margin to drop by 140-240 bps year-on-year in the current fiscal year. It has a couple of launches for FY26 but it still might not be able to compensate for the decline in Revlimid. Analysts have retained 'reduce' rating on the stock, citing muted growth for FY26-27.Cipla has guided operating margin before depreciation and amortisation to fall to 23.5-24.5% in FY26 from 25.9% in the previous year, due to Revlimid patent expiry. Elara Capital expects a further contraction of 300 bps in FY27 as the full loss of Revlimid will be reflected in that year.Cipla's future course of action when it comes to finding a suitor will be another concern that investors may have to grapple with given Torrent Pharmaceuticals ' recent acquisition of JB Chemicals & Pharmaceuticals. According to media reports Torrent was in talks with Cipla to buy majority stake two years ago. But the proposal hit a roadblock due to differences in valuation. Now that Torrent has acquired a stake in JB Chemicals, Cipla's promoters will have to look for other buyers in case they wish to pare stake.On the front of revenue visibility, Cipla has filed for 6 respiratory assets in US, including Symbicort and Qvar and four more to be filed in the next 12-18 months.The generic Advair is expected to be commercialised in this fiscal year. In peptides and complex generics, 9 filings are done, and it aims to file 10 more assets in 12 to 24 months, with two-three filings in FY26 itself.The company has net cash of ₹10,807 crore. It expects to spend 5% of revenue as capex this year, which could be towards mergers and acquisitions. Revenue for FY25 grew by 8.2% year-on-year to ₹2,754.8 crore. Though the company expects a similar growth rate for FY26, Elara anticipates flat-to-low single-digit percentage growth.In FY25, North America business posted a record-high annual revenue of $934 million and $221 million for March 2025 quarter. The company expects June quarter's revenue to be muted at around $220 million."Resolution of supply issues in Lanreotride, the launch of Abraxane and Tasigna and potential launch of Advair and two-three peptide products may not, it seems, be able to compensate for decline in Revlimid in FY26," said Elara, while projecting 6-7% fall in US business for FY26 and FY27. It has downgraded the stock to 'reduce' while lowering target price by 7% to ₹1,465. Emkay Global has reiterated 'reduce' with a TP of ₹1,500 citing execution risks and valuation concerns.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
44 minutes ago
- Business Standard
Torrent Pharma Q1 results: PAT up 20% on robust sales across territories
Torrent Pharmaceuticals on Monday reported a 20 per cent year-on-year (Y-o-Y) rise in consolidated net profit for the June quarter (Q1 FY26) to ₹548 crore, up from ₹457 crore in Q1 FY25, on the back of robust sales across territories. The company's revenue from operations rose to ₹3,178 crore in Q1 FY26, reflecting an 11 per cent Y-o-Y growth from ₹2,815 crore in Q1 FY25. This includes an 11 per cent increase in the company's India revenues, which rose to ₹1,811 crore, led by outperformance in focus therapies. Torrent's chronic business grew at 13 per cent, compared to the Indian Pharma Market's (IPM's) growth of 9 per cent. The Ahmedabad-based pharma major added that it has 21 brands in the top 500 brands in the IPM, with 14 brands having sales of more than ₹100 crore. 'The figure includes acquisition-related one-off expenses of ₹15 crore,' the company said in a statement. Apart from the domestic market, the company also saw growth in revenue from foreign markets. Torrent's revenue from the US market rose by 19 per cent to ₹308 crore, up from ₹259 crore in Q1 FY25. Similarly, revenues from the Brazil market rose by 11 per cent Y-o-Y in Q1 FY26 to ₹218 crore, up from ₹196 crore in the same period last year. The company attributed this growth to the performance of top brands, new launches, and growth in the generic segment. On Monday, Torrent's shares rose marginally by 0.75 per cent, ending the day's trade at ₹3,629.50 apiece on the Bombay Stock Exchange.
Mint
7 hours ago
- Mint
Nifty Pharma Index rises 1% amid weak India Stock Markets: Cipla and Laurus Labs among key gainers
Stock Market Today: The Nifty Pharma Index gained more than 1% amid a weak Indian stock market on a day when the benchmark Nifty 50 Index dipped 0.3-0.4% during the intraday trades. Cipla and Laurus Labs stood among the key gainers The Nifty Pharma index, showing its resilience, gained more than 1% during the intraday trades. The Nifty Pharma Index, which opened at 22690.50 on Monday, went to scale highs of 22,908.40, marking gains of more than 1% over the previous day's close of 22662.70. Laurus Labs, with gains of more than 7%, followed by Cipla, with gains of close to 2%, stood among key gainers. Glenmark Pharmaceuticals and Gland Pharma also gained more than 1%, helping drive gains. Nifty Pharma and Healthcare index have been showing resilience amid volatile stock markets since last few weeks While Nifty Pharma & Healthcare are the lone warriors displaying outperformance amidst this downfall in the markets, we expect sectors such as IT, Defense, Oil & Gas, Realty & CPSE to appear bearish and may continue to underperform in the near term, given their weak price structures and lackluster momentum indicators., said Sudeep Shah, Vice President and Head of Technical and Derivative Research, SBI Securities Technically, Cipla, Apollo Hospital are likely to outperform in the short term, as per Shah. The Indian Pharma index performance is also being helped by strong Indian Pharma market growth. The IPM growth during the month of June 2025 stood at a strong 11.5%, as per reports. Glemmark Pharmaceuticals, JB Chemicals and Pharmaceuticals, Mankind Pharma FDC Ltd, Alkem, Zydus, and Torrent were among the key outperformers as per Nuvama. While the pharma market is growing, the challenge is provided by rising generic sales and Jan Aushadhi Kendras. However, amidst challenges, Within formulations, Sun, Cipla, Lupin and Emcure are the top picks. of Kotak Institutional Equities Disclaimer: The views and recommendations above are those of individual analysts or brokerage companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
Time of India
8 hours ago
- Time of India
TCS revenue to slow sharply in FY26, says Elara as it downgrades stock and cuts target price
Tata Consultancy Services is set for weaker revenue growth in FY26 compared with last year, as persistent macroeconomic pressures, delayed project ramp-ups, and subdued discretionary spending weigh on demand, brokerage Elara Capital said while downgrading the stock to 'accumulate' from 'buy', and trimming its price target. Elara slashed its target price on TCS to Rs 3,770 from Rs 3,970, citing broad-based weakness across key markets and verticals. Explore courses from Top Institutes in Please select course: Select a Course Category PGDM Operations Management Public Policy healthcare Data Science MBA others Finance Design Thinking Degree Leadership CXO Management Data Analytics Healthcare Cybersecurity Product Management Digital Marketing MCA Data Science Others Project Management Artificial Intelligence Technology Skills you'll gain: Financial Analysis & Decision Making Quantitative & Analytical Skills Organizational Management & Leadership Innovation & Entrepreneurship Duration: 24 Months IMI Delhi Post Graduate Diploma in Management (Online) Starts on Sep 1, 2024 Get Details by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Elegant New Scooters For Seniors In 2024: The Prices May Surprise You Mobility Scooter | Search Ads Learn More Undo The brokerage cited a combination of sectoral and macroeconomic pressures for its downgrade. Elara pointed to sustained scrutiny of discretionary spending, the impact of a new tariff order on sectors such as pharmaceuticals, reduced energy-sector budgets due to policy shifts and geopolitical tensions, and subdued BFSI demand in Europe and the UK. TCS reported weaker-than-expected Q1 FY26 revenue, declining 0.6% quarter-on-quarter in dollar terms and 3.3% on a constant currency basis, while year-on-year revenue slipped 1.1%. In rupee terms, revenue was down 1.6% from the previous quarter. North America saw a 2.7% annual drop, while the UK and continental Europe recorded constant-currency declines of 1.3% and 3.1%, respectively. The sharpest fall came from the India business, which plunged 31.4% sequentially and 23.5% year-on-year in dollar terms, reducing its contribution to overall revenue to 5.8% from 8.4% in the prior quarter. Live Events Vertical-wise, Consumer, Life Sciences, Manufacturing, and Communications fell by 3–9% YoY (in constant currency), while BFSI and Tech showed modest growth. TCS's total contract value (TCV) stood at $9.4 billion for Q1FY26, down 23% QoQ but up 13% YoY, within its guidance of $7–9 billion. Revenue and margin outlook 'Given weak Q1 and seasonal weakness in H2, we expect revenue growth in FY26 to be much lower than in FY25,' Elara said, cutting its FY26E, FY27E, and FY28E revenue estimates. It now forecasts a ~1% revenue drop in FY26, against its earlier estimate of 2% growth, while projecting moderate recovery with ~3.5% growth in FY27. EBIT margin expanded 30 basis points QoQ to 24.5%, aided by a 73% reduction in costs related to the BSNL deal, which fell to about 1% of sales from over 4% in previous quarters. However, Elara trimmed its FY26E and FY27E EBIT margin assumptions by 50–60 basis points, citing 'a rise in attrition and possible further pressure on margin due to the new BSNL deal.' TCS is yet to decide on wage hikes for FY26 amid an uncertain demand environment. Last-twelve-month attrition stood at 13.8%, above its comfort range of 11–13%. Sector backdrop and stock reaction The downgrade comes as India's IT sector faces continued pressure, with large-cap tech stocks sliding on Monday. TCS shares fell 1.7% to Rs 3,081.60 after announcing a 2% cut in its global workforce, around 12,000 employees, due to weak discretionary spending and macro headwinds. Wipro fell 3.5% to Rs 250.05, Infosys lost 2.2% to Rs 1,482.50, while HCL Tech and Tech Mahindra also ended lower. The Nifty IT index dropped 1.6%, extending its decline to 24% from its recent peak. Despite near-term challenges, TCS highlighted strong momentum in AI-led services during Q1FY26, with over 114,000 employees trained in advanced AI skills. Also read | Reliance Power shares down 15% in a month as ED probe drags. Can the stock reclaim Rs 70 amid volatility? ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
